Non-coding RNAs as key regulators of Gasdermin-D mediated pyroptosis in cancer therapy

Gaurav Gupta1, Muhammad Afzal2, Ehssan Moglad3

  • 1Centre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401, India; Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates.

PubMed

Insights

Non-coding RNAs (ncRNAs) interact with Gasdermin-D, a key protein in pyroptosis, offering new anticancer therapy strategies. Understanding these interactions can help regulate pyroptosis for effective cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Death Research

Background:

  • Pyroptosis is a programmed cell death pathway critical in cancer therapeutics.
  • Gasdermin-D is an essential effector protein that executes pyroptosis.
  • Dysregulation of pyroptosis contributes to cancer progression and therapeutic resistance.

Purpose of the Study:

  • To review the interactions between Gasdermin-D and non-coding RNAs (ncRNAs).
  • To explore the potential of these interactions in regulating pyroptosis for cancer therapy.
  • To identify therapeutic strategies based on ncRNA-mediated Gasdermin-D regulation.

Main Methods:

  • Literature review of studies on pyroptosis, Gasdermin-D, and ncRNAs.
  • Analysis of molecular mechanisms involving ncRNAs as competing endogenous RNAs (ceRNAs).
  • Synthesis of current research findings on ncRNA-Gasdermin-D interactions in cancer.

Main Results:

  • ncRNAs, including lncRNA, miRNA, and siRNA, significantly influence Gasdermin-D expression and function.
  • ncRNAs can act as ceRNAs to modulate Gasdermin-D at the molecular level.
  • These interactions are implicated in controlling cancer cell death and tumor propagation.

Conclusions:

  • ncRNAs are key mediators in regulating Gasdermin-D and pyroptosis.
  • Targeting ncRNA-Gasdermin-D interactions presents promising therapeutic avenues for cancer treatment.
  • Optimizing pyroptosis through ncRNA modulation offers a novel strategy for cancer therapy.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.2K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Types of RNA01:23

Types of RNA

Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
63.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K